List view / Grid view
15 September 2015 | By Victoria White
Data show that Tresiba U200 significantly lowers both rates of hypoglycaemia and mean fasting blood glucose compared to insulin glargine U100 in patients with type 2 diabetes...
15 September 2015 | By Victoria White
Not only are Saxenda 'early responders' more likely to achieve greater weight loss, they are also more likely to experience greater improvements in cardiometabolic risk factors...
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
2 September 2015 | By Victoria White
New TECOS study findings have shown that patients with type-2 diabetes can safely take sitagliptin without an increased risk of cardiovascular complications...
27 August 2015 | By Nick Jackson
Synjardy approval was based on multiple clinical trials showing reductions in blood glucose versus placebo...
25 August 2015 | By Victoria White
Novo Nordisk has announced headline results from the final Phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes...
20 August 2015 | By Victoria White
Boehringer Ingelheim and Lilly have announced positive top-line results from a clinical study investigating cardiovascular (CV) outcomes for Jardiance...
17 August 2015 | By Victoria White
The number of people living with diabetes in the UK has soared by nearly 60% in a decade, according to a new analysis by Diabetes UK...
4 August 2015 | By Victoria White
Toujeo is now available in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition...
29 July 2015 | By Victoria White
Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin...
23 July 2015 | By Victoria White
The global market for type 2 diabetes mellitus therapeutics will rise in value from $23.5 billion in 2014 to an estimated $39 billion by 2021, driven primarily by rising disease prevalence and the continued uptake of recently approved and emerging branded treatments, according to business intelligence provider GBI Research.
22 July 2015 | By Victoria White
NICE has recommended aflibercept solution for injection and dexamethasone implant as treatment options for some people with diabetic macular oedema...
15 July 2015 | By Victoria White
Lilly has released an Android version of its Glucagon Mobile application designed for caregivers and healthcare providers who support people with diabetes...
2 July 2015 | By Victoria White
Novo Nordisk has decided to cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany...
1 July 2015 | By Victoria White
Vitae has announced top-line efficacy results from the metformin arm of a trial of BI187004/VTP-34072 in the treatment of patients with type 2 diabetes...
